Having established that SIGLEC1 is significantly expressed only by Br-TAM, we performed immunofluorescent staining using anti-SIGLEC1 and anti-CD163 antibodies on tissue biopsies from patients with invasive breast cancer and benign lesions (Figure 4E). Here, CD163 is linked to invasive breast carcinoma.